Use of Cerenkov Luminescence Imaging (CLI) for monitoring preclinical cancer treatment is described here. This method takes advantage of Cerenkov Radiation (CR) and optical imaging (OI) to visualize radiolabeled probes and thus provides an alternative to PET in preclinical therapeutic monitoring and drug screening.
The overall goal of this procedure is to use OV luminescence imaging to monitor cancer therapy in tumor bearing mice. This is accomplished by first growing subcutaneous tumor xenografts for both treatment and control groups. The second step is to perform small animal PET studies for validation purposes.
Next, the optical imaging studies are performed immediately after PET studies. The final step involves quantifications of PET and clea images and subsequent cross validations of the two imaging modalities. Ultimately, results are obtained to show that CLEA is a viable alternative to pet in monitoring preclinical cancer drug therapy.
繁體中文
